

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Scott L. Weinrich et al.

For: PRODUCING TELOMERASE ACTIVATORS
AND INHIBITORS BY SCREENING WITH
PURIFIED TELOMERASE

INFORMATION DISCLOSURE STATEMENT

PURSUANT TO 37 CFR § 1.98(d)


Commissioner for Patent
Alexandria, VA 22313

Dear Sir:

The information listed in the accompanying form PTO-1449 may be material to examination of this application and are submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

Copies of the information are not provided herewith, but were previously filed in grandparent application 09/717, 828, to which this application claims priority under 35 USC § 120. The Examiner is respectfully directed to the file for application 09/717, 828 to access the information listed on the accompanying form PTO-1449. This is in compliance with the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, or that the information listed on the accompanying PTO-1449 is material to patentability of the claimed invention under 37 CFR § 1.56(b).



J. Michael Schiff
Registration No. 40,253

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7715
Fax: (650) 473-8654

March 26, 2004

Form 1449 (modified)		Docket: 011/007d	U.S.S.N.
Information Disclosure		Producing Telomerase Activators and Inhibitors by Screening with Purified Telomerase	
Statement By Applicant		Inventors: Scott L. Weinrich et al.	
		Filing Date: March 26, 2004	Examiner: Tekchand Saidha, Ph.D. Group: 1652

U.S. Patent Documents

Examiner Initial	Ref.	Patent No.	Filing Date	Issue Date	Class/ Subclass	Inventors:	Title:
	A	5,489,508	3/24/93	2/6/96	435/6	West, M., et al.	Therapy and Diagnosis of Conditions Related to Telomere Length and/or Telomerase Activity
	B	5,583,016	10/27/94	12/10/96	435/91.3	Villeponteau, B., et al.	Mammalian Telomerase
	C	5,639,613	4/18/95	6/17/97	435/6	Shay, J., et al.	Methods for Cancer Diagnosis and Prognosis
	D	5,698,686	4/28/95	12/16/97	536/23.1	Gottschling, D., et al.	Yeast Telomerase Compositions
	E	5,747,317	6/8/96	5/5/98	435/194	Cao, Z.	Human Telomerase RNA Interacting Protein Gene
	F	5,770,422	7/8/96	6/23/98	435/194	Collins, K.	Human Telomerase
	G	5,858,777	9/13/96	1/12/99	435/325	Villeponteau, B., et al.	Methods and Reagents for Regulating Telomere Length and Telomerase Activity
	H	5,888,747	5/4/98	3/30/99	435/7.1	Cao, Z.	Human Telomerase Gene RNA Interacting Protein Gene
	I	5,916,752	9/26/97	6/29/99	735/6	Gottschling, D., et al.	Telomerase Screening Methods
	J	5,917,025	6/16/98	6/29/99	536/23.2	Collins, K.	Human Telomerase
	K	6,093,809	5/6/97	7/25/00	536/23.5	Cech, et al.	Telomerase

Foreign Patent or Published Foreign Patent Application

Examiner Initial	Ref.	Document No.	Publ. Date	Juris-diction	Title:		Translation Yes	Translation No
	L	WO 94/03205	2/17/94	PCT	HLA Binding Peptides and Their Uses			
	M	WO 95/13382	5/18/95	PCT	Therapy and Diagnosis of Conditions Related to Telomere Length and/or Telomerase Activity			
	N	WO 96/01614	1/25/96	PCT	RNA Component of Telomerase			
	O	WO 96/01825	1/25/96	PCT	Heterobicyclic Derivatives			
	P	WO 96/01835	1/25/96	PCT	Mammalian Telomerase			
	Q	WO 96/12811	5/2/96	PCT	Yeast Telomerase Components and Methods Using Them			
	R	WO 96/19580	6/27/96	PCT	Telomerase Protein Component			
	S	WO 96/40868	12/19/96	PCT	Essential Oligonucleotides of Vertebrate Telomerase			

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)		Docket: 011/007d	U.S.S.N.
Information Disclosure		Producing Telomerase Activators and Inhibitors by Screening with Purified Telomerase	
Statement By Applicant		Inventors: Scott L. Weinrich et al.	
		Filing Date: March 26, 2004	Examiner: Tekchand Saidha, Ph.D. Group: 1652

Examiner Initial	Ref.	Document No.	Publ. Date	Juris-diction	Title:	Translation	
						Yes	No
	T	WO 98/14593	4/9/98	PCT	Human Telomerase Catalytic Subunit		
	U	WO 98/45450	10/15/98	PCT	Purified Telomerase		

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source
	V	Blackburn, E.H., "Telomerases", Annu. Rev. Biochem, 61:113-29 (1992)
	W	Blackburn, E.H., et al., "A Conserved Secondary Structure for Telomerase RNA", Cell, 67:343-353 (1991)
	X	Blackburn, E.H., et al., "Telomeres", TIBS, 16:378-381 (1991)
	Y	Bochnig, P., et al., "A Monoclonal Antibody Against 2,2,7-trimethylguanosine that Reacts with Intact Class U, Small, Nuclear Ribonucleoproteins as well as with 7-Methyl-Guanosine-Capped RNAs", Eur. J. Biochem., 168:461-476 (1987)
	Z	Counter, et al. , "Telomerase Activity in Human Ovarian Carcinoma", Proc. Natl. Acad. Sci. USA, 91:2900-2904 (1994)
	AA	Feng, J., et al., "The RNA Component of Human Telomerase", Sci., 269(5228):1236-1241 (1995)
	AB	Graham, et al., "Characteristics of Human Cell Line Transformed by DNA from Human Adenovirus Type 5", J. Gen. Virol., 26:59-77 (1977)
	AC	Harley, C.B., "Telomere Loss: Mitotic Clock or Genetic Time Bomb?", Mutation Res., 256:271-282 (1991)
	AD	Lingner, J., et al., "Purification of Telomerase from Euplotes Aediculatus: Requirement of a Primer 3' Overhang", Proc. Natl. Acad. Sci. USA, 93:10712-10717 (1996)
	AE	Lingner, J., et al., "Telomerase RNAs of Different Ciliates Have a Common Secondary Structure and a Permuted Template", Genes and Devel., 8:1984-1988 (1994)
	AF	Miller, et al., "Improved Retroviral Vectors for Gene Transfer and Expression", Biotechniques, 7:980-990 (1992)
	AG	Morin, G., "The Human Telomere Terminal Transferase Enzyme is a Ribonucleoprotein that Synthesizes TTAGGG Repeats", Cell, 59:521-529 (1989)
	AH	Nakamura, T., et al., "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human", Science, 277:955-959, (1997)
	AI	Nomura, N., et al., "Prediction of the Coding Sequences of Unidentified Human Genes", DNA Res., 1:27-35 (1994)
	AJ	Nomura, N., et al., Accession D21163 Genbank Sequence
	AK	Schnapp, et al., "One Step Affinity Purification Protocol for Human Telomerase", Nucleic Acids Res., 26(13):3311-3313 (1998)
	AL	Singer, M., et al, "TLC1: Template RNA Component of <i>Saccharomyces Cerevisiae</i> Telomerase", Science, 266:404-409 (1994)
	AM	Srivastava, M., et al., "Genomic Organization and Chromosomal Localization of the Human Nucleolin Gene", Jour. Of Bio. Chem., 265(25):14922-14931 (1990)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)	Docket: 011/007d U.S.S.N.
Information Disclosure	Producing Telomerase Activators and Inhibitors by Screening with Purified Telomerase
Statement By Applicant	Inventors: Scott L. Weinrich et al.
	Filing Date: March 26, 2004 Examiner: Tekchand Saidha, Ph.D. Group: 1652

Examiner Initial	Ref.	Author, Title, Date, Source
	AN	Stillman, et al., "Replication and Supercoiling of Simian Virus 40 DNA in Cell Extracts from Human Cells", Mol. And Cell Bio., 5:2051-2060 (1985)
	AO	Villeponteau, B., et al., "Mammalian Telomerase", US Patent Application 09/060,523, Filed 4/14/98
	AP	Derwent Summary of JP 07 242 566A, "An Immunosuppressant Contg. Human Nucleolin Antibody – Is Effective Against Autoimmune Disease"
	AQ	Derwent Summary of JP 9154575A, "Telomerase Useful in Diagnosis of Tumours – Comprises RNA Protein Having Aggregate Containing Protein Located At Terminal Region of Human Chromosome"
	BA	"Characterization and Expression of Human Telomerase", Ph.D. Thesis by Ariel Athena Avilion, State University of New York at Stony Brook, dated May 1995.

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**